XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The new plant will manufacture high-quality Type I borosilicate glass tubing
Subscribe To Our Newsletter & Stay Updated
